PTEN and Egr-1 expression in thyroid proliferative lesions

Area of Science:

• Oncology
• Molecular Biology
• Pathology

Background:

• PTEN acts as a tumor suppressor by inhibiting cell cycle progression.
• Emerging evidence indicates that Egr-1 can upregulate PTEN transcription.
• Understanding the interplay between PTEN and Egr-1 in thyroid lesions is crucial for cancer research.

Purpose of the Study:

• To investigate the immunohistochemical expression of PTEN and Egr-1.
• To compare PTEN and Egr-1 expression in normal thyroid tissue versus benign and malignant thyroid proliferative lesions.

Main Methods:

• Immunohistochemistry was employed to assess PTEN and Egr-1 expression.
• Quantitative analysis of positive staining in normal thyroid, nodular hyperplasia, adenoma, papillary carcinoma, follicular carcinoma, and undifferentiated carcinoma.
• Statistical analysis to determine significant differences in expression levels.

Main Results:

• PTEN cytoplasmic expression was high in normal thyroid, nodular hyperplasia, adenoma, and papillary carcinoma.
• A significant decrease in PTEN expression was observed in follicular and undifferentiated carcinomas.
• Egr-1 nuclear expression was similar in normal tissue, nodular hyperplasia, and papillary carcinoma.
• Significant reductions in Egr-1 expression were noted in adenomas, follicular carcinomas, and undifferentiated carcinomas.

Conclusions:

• PTEN expression is maintained in most benign thyroid conditions but significantly reduced in advanced malignant types.
• Egr-1 expression shows a notable decrease in several benign and malignant thyroid lesions, differing from PTEN expression patterns.
• The study highlights altered PTEN and Egr-1 expression in thyroid proliferative lesions, suggesting their potential roles in thyroid tumorigenesis.